英国剑桥大学的研究团队在帕金森病药物研发领域取得重大突破，利用人工智能（AI）技术将药物设计速度提升了整整十倍。据《科技日报》报道，该团队通过开发并应用AI驱动的策略，成功地识别出能够阻止α-突触核蛋白聚集的小分子，这种蛋白的异常聚集是帕金森病的主要病理特征。
研究人员表示，利用AI进行的智能筛选大大加快了药物发现的初期阶段，不仅将速度提高了10倍，还将成本降低了99%，显著降低了新疗法研发的经济负担。这一创新方法使得帕金森病潜在治疗方案的开发时间大幅缩短，为患者带来了新的希望。
该研究的成果已发表在最新一期的《自然·化学生物学》杂志上，彰显了AI在生物医药研究领域的巨大潜力。这一突破性进展预示着未来帕金森病的治疗将可能更快地进入临床试验阶段，为全球数百万帕金森病患者提供更有效、更及时的治疗选择。
英语如下：
**News Title:** “Cambridge University利用AI to Accelerate Parkinson’s Drug Development by 10 Times!”
**Keywords:** AI制药, 帕金森病, 剑桥研究
**News Content:** A research team from the University of Cambridge in the UK has made a significant breakthrough in Parkinson’s disease drug development, utilizing artificial intelligence (AI) technology to speed up the drug design process by a factor of ten. As reported by the *Science and Technology Daily*, the team successfully identified small molecules capable of preventing the aggregation of α-synuclein protein, an abnormal clustering that is the primary pathological feature of Parkinson’s disease, through the development and application of AI-driven strategies.
Researchers noted that AI-enabled intelligent screening significantly expedited the initial stages of drug discovery, not only boosting speed by a factor of ten but also reducing costs by 99%, thereby alleviating the financial burden of developing new therapies. This innovative approach has shortened the timeline for potential Parkinson’s treatments, offering new hope to patients.
The findings of this study have been published in the latest issue of *Nature Chemical Biology*, highlighting the tremendous potential of AI in biomedical research. This breakthrough progress suggests that future treatments for Parkinson’s may more rapidly advance to clinical trial stages, providing millions of Parkinson’s patients worldwide with more effective and timely treatment options.
【来源】http://digitalpaper.stdaily.com/http_www.kjrb.com/kjrb/html/2024-04/22/content_570458.htm?div=-1
Views: 1